{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:41:31Z","timestamp":1773153691207,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We report the successful use of repeated administration of rituximab in a patient with antisynthetase syndrome refractory to conventional immunosuppressive medications. A literature review revealed that previous experience with rituximab in this condition has been sparse. The rationale for the use of B\u2010cell depleting therapies in antisynthetase syndrome has been explored in light of the current understanding of the pathogenesis of this condition.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2011.02702.x","type":"journal-article","created":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T14:32:17Z","timestamp":1332340337000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of rituximab in refractory antisynthetase syndrome"],"prefix":"10.1111","volume":"42","author":[{"given":"V.","family":"Limaye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Hissaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.\u2010L.","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Koszyka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"key":"e_1_2_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2008.01822.x"},{"key":"e_1_2_2_3_2","first-page":"692","article-title":"Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations","volume":"16","author":"Hengstman GJD","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"e_1_2_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(96)80026-6"},{"key":"e_1_2_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100670070030"},{"key":"e_1_2_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029694"},{"key":"e_1_2_2_7_2","article-title":"A three way interplay of DR4, autoantibodies and synovitis in biopsy\u2010proven idiopathic inflammatory myositis","author":"Limaye V","year":"2010","journal-title":"Rheumatol Int"},{"key":"e_1_2_2_8_2","first-page":"1009","article-title":"Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature","volume":"27","author":"Rios Fernandez R","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20849"},{"key":"e_1_2_2_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.045898"},{"key":"e_1_2_2_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/08916930600623791"},{"key":"e_1_2_2_12_2","first-page":"1369","article-title":"Efficacy of rituximab in refractory polymyositis","volume":"32","author":"Lambotte O","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep157"},{"key":"e_1_2_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0859-x"},{"key":"e_1_2_2_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-04-0624"},{"key":"e_1_2_2_16_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.037"},{"key":"e_1_2_2_17_2","first-page":"599","article-title":"Increase of CA 19.9 in dysimmune inflammatory rheumatism. Apropos of 6 cases","volume":"61","author":"Cantagrel A","year":"1994","journal-title":"Rev Rhum Ed Fr"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2011.02702.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2011.02702.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T06:03:13Z","timestamp":1697349793000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2011.02702.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1445-5994.2011.02702.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2011.02702.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"2012-03-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}